New to the Huntington's Disease Lighthouse?
 Welcome to the HDlighthouse!
 Getting started.
 
Home \ Research \ Drugs and Supplements \ Updates
Creatine Supplementation Lowers Brain Glutamate Levels in HD patients

HD Lighthouse Contributing Editor's Comment: Short term trials of creatine have not yielded positive results despite good results in mouse models. This new study of brain metabolite levels in HD patients shows that creatine supplementation improves glutamate metabolism, known to be impaired with HD. Longer term clinical trials of creatine are warranted.
--Marsha L. Miller, Ph.D.
Posted to the HDL: 29 Jan 2005



Creatine supplementation lowers brain glutamate levels in Huntington's disease

There is evidence from in vitro and animal experiments that oral creatine (Cr) supplementation might prevent or slow down neurodegeneration in Huntington's disease (HD). However, this neuroprotective effect could not be replicated in clinical trials, possibly owing to treatment periods being too short to impact on clinical endpoints. We used proton magnetic resonance spectroscopy ((1)H-MRS) as a surrogate marker to evaluate the effect of Cr supplementation on brain metabolite levels in HD.Twenty patients (age 46+/-7.3 years, mean duration of symptoms 4.0+/-2.1 years, number of CAG repeats 44.5+/-2.7) were included. The primary endpoint was metabolic alteration as measured by (1)H-MRS in the parieto-occipital cortex before (t1) and after 8-10 weeks (t2) of Cr administration. Secondary measures comprised the motor section of the Unified Huntington's Disease Rating Scale and the Mini Mental State Examination. (1)H-MRS showed a 15.6% decrease of unresolved glutamate (Glu)+glutamine (Gln; Glu+Gln=Glx; p<0.001) and a 7.8% decrease of Glu (p<0.027) after Cr treatment. N-acetylaspartate trended to fall (p=0.073) whereas total Cr, choline-containing compounds, glucose, and lactate remained unchanged. There was no effect on clinical rating scales.This cortical Glx and Glu decrease may be explained by Cr enhancing the energy-dependent conversion of Glu to Gln via the Glu-Gln cycle, a pathway known to be impaired in HD. Since Glu-mediated excitotoxicity is presumably pivotal in HD pathogenesis, these results indicate a therapeutic potential of Cr in HD. Thus, longterm clinical trials are warranted.

Tracked on the Lighthouse:
creatine

# # #

Source: J Neurol. 2005 Jan;252(1):36-41

print this
printer friendly
version

 

Read the HDAC/HDLighthouse Forum. Post your comments
   
Related Topics
Research focusing on the formation of aggregates caused by HD
 
Research related to the role Brain Derived Neurotrophic Factor has on the pathology of HD in the brain
 
Research related HD and it's general affect on the brain
 
Learn more about the clinical trial process, trials that have been conducted and those that are underway.
 
Research focusing on gene therapy.
 
Research focusing on gene transcription.
 
General research related to HD
 
Research studying the genetics of Huntington's Disease
 
Research studying the Immune System and it's effect on the progression of HD
 
Research studying the brain tissue and research related to stem cells
 
Recent Updates
17 Aug 2008
FDA approves tetrabenazine
The FDA approves the first drug specifically for Huntington
 
19 Jul 2008
The FDA approves a Phase IIB clinical trial for ACR16
Neurosearch will begin recruiting for the trial later this year.
 
7 Jul 2008
Encouraging results from the Phase II Dimebon trial
Dimebon was found to be safe and well tolerated and there are indications of effectiveness.
 
24 Mar 2008
Approved drugs found to induce autophagy
UK researchers have found promising drugs which induce autophagy, an alternate way to clear away the HD protein.
 
5 Jan 2008
Zoloft raises BDNF, helps the HD mice
Sertaline (Zoloft) improves symptoms, reduces brain atrophy, and prolongs survival in the R6/2 mice.
 
1 Jan 2008
Screening Yields a Promising Compound
High throughput screening has identified a compound which inhibits protein aggregation. Part 1 of 3.
 
1 Jan 2008
C2-8 Suppresses Neurodegeneration in Drosophilia
C2-8 moves another step on the research pipeline with success in a fruitfly model of HD. Part 2 of 3.
 
1 Jan 2008
C2-8 Slows Progression in HD Mice
R6/2 mice given C2-8 experience delayed progression of motor symptoms and reduced cell death. Part 3 of 3
 
4 Dec 2007
Buck Institute and Neurobiological Technologies, Inc. Partner to Develop Treatment for HD
Following promising results in mouse models, researchers at Buck Institute and NTI will work on developing FGF-2 as a drug for HD patients.
 
19 Nov 2007
Miraxion results look promising
One more Phase III clinical trial is needed to support a New Drug Application.
 

All Updates for Drugs and Supplements
Disclaimer & Privacy Policy | Welcome | Site Feedback Marsha@HDLighthouse.org